Sohini Das

Indian drugmakers in no rush to shift to US despite tariff threat

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Ramkrishna Forgings expects exports to recover on stronger global orders

The company expects exports to contribute 35 per cent of FY27 revenue as demand improves in North America and Europe, helping absorb newly created manufacturing capacity

M&M eSUV biz shifts gear from ₹101 cr loss to ₹288 cr profit in a year

Revenue rises 77% YoY; PBIT margin improves 860 bps as XEV 9S drives volumes, EV penetration

M&M Q1 PAT rises 34% to ₹5,455 crore; revenue grows 28% to ₹58,188 cr

Auto and farm profits rise 18%; services PAT jumps 80% on improved performance at MMFSL and Tech Mahindra

Mahindra's EV arm turns unicorn with ₹322 crore funding, IPO on track

Rs 322-crore funding led by Lightrock values Mahindra Last Mile Mobility at Rs 10,822 crore as the company targets a second-half FY27 listing

RPG Life Sciences carves out API arm; InvAscent to invest up to ₹243 crore

Company scouts for USFDA-approved assets; on track for ₹1,000 crore in revenue by FY28

Regulatory hurdles eclipse tariff worries for pharma CXOs: Deloitte survey

Industry seeks AI-based submission tools and unified digital portals to accelerate approvals and compliance tracking

The reform booster shot that transformed India into pharmacy of the world

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

Fermenta Biotech expands plant-based Vitamin D3 capacity at Dahej plant

Dahej facility to begin commercial production in FY28; company targets nutraceuticals, functional foods and import substitution

Camso, premium push put tyremaker Ceat on growth track; costs cloud FY27

Tyre maker expects premium products, exports and Camso integration to support growth, while higher raw-material costs, freight and geopolitical risks weigh on margins

Dr Reddy's antibiotic gets Thailand approval six months after US nod

Thailand has become the second country after the US to approve Dr Reddy's first-in-class antibiotic zoliflodacin, a milestone that could accelerate access to the drug across emerging markets

Electric car race widens as new entrants gain traction in H1 CY26

Maruti, VinFast and Tesla capture 8.1% market, account for 18% of incremental registrations

Maruti targets 25-30% growth in SUV sales in FY27 on new Brezza, launches

SUV contribution to Maruti Suzuki's domestic sales has risen from 12 per cent in FY23 to around 30 per cent in the first quarter of FY27

We can theoretically become net-debt zero after IPO: Manipal Health's Jose

MD & CEO Dilip Jose says the hospital chain will use the ₹8,000-crore fresh issue largely to repay debt, while pursuing organic expansion and selective acquisitions in key markets

Maruti repositions Brezza as first-time buyers reshape compact SUV market

The refreshed Brezza will target first-time, replacement and additional-car buyers as Maruti responds to changing preferences and intensifying competition in compact SUVs

Sona Comstar eyes 10x revenue growth with robotics, AI and acquisitions

The auto components maker aims to replicate the ten-fold growth achieved over the past decade, backed by robotics, physical AI, acquisitions and new mobility technologies

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Bajaj Auto Q1 profit jumps 46% as record volumes and exports fuel growth

Bajaj Auto to raise annual production capacity to over 9 million vehicles

Q1FY27 pharma preview: Domestic growth cushions US-led pressure on earnings

Hospitals and diagnostics are expected to outperform in Q1FY27, driven by capacity additions, improving utilisation and higher patient volumes despite pressure on margins

Lupin spins out 2 cancer drug programmes into US-based Kaveri Therapeutics

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding